Our searches related to BAFF and anti-GBM disease identified only one paper on serum BAFF levels in patients with anti-GBM disease, but we found no animal studies involving anti-BAFF agents (belimumab, atacicept, tabalumab, or blisibimod) and no clinical studies (RCT, cohort study, or case report) involving these drugs. This evidence concerns the gene TNFSF13B and glioblastoma.